Clinical Trial Update: Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and immunogenicity of Takeda's norovirus GI.1/GII.4 bivalent virus-like particle vaccine in healthy volunteers; results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Infection

Drugs mentioned

• Norovirus GI.1/GII.4 bivalent virus-like particle vaccine (Norovirus GI.1/GII.4 virus-like particle vaccine)

Snippet

Sponsor: Takeda | Conditions: Healthy Volunteers, Norovirus, Prevention | Phase 2 | Status: COMPLETED | Results posted: 2016-08-01